No CrossRef data available.
Article contents
Acute lower extremity ischaemia after surgical interventricular communication closure in a newborn
Part of:
Interventional Cardiology
Published online by Cambridge University Press: 13 September 2021
Abstract
We report a 5-month-old infant who developed an unexpected acute ischaemia of the right lower limb following a surgical perimembranous interventricular communication closure. This rare case of ischaemia was due to an occlusive right common iliac artery dissection. It was early managed by angioplasty with two ABSORB® bioresorbable stents, resulted in complete revascularisation of the right leg.
Keywords
- Type
- Brief Report
- Information
- Copyright
- © The Author(s), 2021. Published by Cambridge University Press
References
Taub, PJ, O’Connell, JP, Singh, A, et al. Acute ischemia of the lower extremity in the pediatric population: a protocol for management. Mt Sinai J Med 2006; 73: 1074–1078.Google ScholarPubMed
Matos, JM, Fajardo, A, Dalsing, MC, Motaganahalli, R, Akingba, GA, Murphy, MP. Evidence for nonoperative management of acute limb ischemia in infants. J Vasc Surg 2012; 55: 1156–1159.10.1016/j.jvs.2011.09.092CrossRefGoogle ScholarPubMed
Monagle, P, Chan, AKC, Goldenberg, NA, et al. antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141 (Suppl 2): e737S–e801S.10.1378/chest.11-2308CrossRefGoogle ScholarPubMed
Smits, PC, Chang, CC, Chevalier, B, et al. Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial. EuroIntervention 2020; 16: 645–653.CrossRefGoogle ScholarPubMed
Serruys, PW, Chevalier, B, Sotomi, Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet 2016; 388: 2479–2491.CrossRefGoogle ScholarPubMed
Varcoe, RL, Schouten, O, Thomas, SD, Lennox, AF. Initial experience with the absorb bioresorbable vascular scaffold below the knee: 6-month clinical and imaging outcomes. J Endovasc Ther 2015; 22: 226–232.10.1177/1526602815575256CrossRefGoogle Scholar
Varcoe, RL, Schouten, O, Thomas, SD, Lennox, AF. Experience with the absorb everolimus-eluting bioresorbable vascular scaffold in arteries below the knee: 12-month clinical and imaging outcomes. JACC Cardiovasc Interv 2016; 9: 1721–1728.CrossRefGoogle ScholarPubMed
Varcoe, RL, Thomas, SD, Lennox, AF. Three-year results of the absorb everolimus-eluting bioresorbable vascular scaffold in infrapopliteal arteries. J Endovasc Ther 2018; 25: 694–701.CrossRefGoogle ScholarPubMed
Dia, A, Venturini, JM, Kalathiya, R, et al. Single arm retrospective study of bioresorbable vascular scaffolds to treat patients with severe infrapopliteal arterial disease. Catheter Cardiovasc Interv 2019; 94: 1028–1033.CrossRefGoogle ScholarPubMed
Kum, S, Ipema, J, Chun-Yin, DH, et al. Early and midterm experience with the absorb everolimus-eluting bioresorbable vascular scaffold in Asian patients with chronic limb-threatening ischemia: 1-year clinical and imaging outcomes from the DISAPEAR registry. J Endovasc Ther 2020; 27: 616–622.CrossRefGoogle ScholarPubMed